Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasburicase for Hyperuricemia in Pediatric Hematological Malignancies
NCT00290992Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2005
- Primary completion
- Apr 2006
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rasburicase in hyperuricemia and tumor lysis syndrome (TLS) (2 arms), sponsored by Sanofi. Primary endpoint: Uric Acid Response Rate at Day 5. Started Jun 2005; status: completed.
02
Drugs
rasburicase
03
Conditions
hyperuricemiatumor lysis syndrome (TLS)
Beyond the preview
Go deeper on NCT00290992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00290992.